Andrew H. Shennan

Andrew H. Shennan

Auto-generated profile, based on publicly available information

Andrew H. Shennan

Department of Women and Children's Health St Thomas' Hospital, King's College London London UK

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Placenta
Verified
Journal Article
Open access
SBSamantha J. Benton
Samantha J. Benton
LMLesley M. McCowan
Lesley M. McCowan
AHAlex Heazell
Alex Heazell
DGDavid Grynspan
David Grynspan
JHJennifer A. Hutcheon
Jennifer A. Hutcheon
PDPeter von Dadelszen
Peter von Dadelszen
Discriminating between placentally-mediated fetal growth restriction and constitutionally-small fetuses is a challenge in obstetric practice. Placental growth factor (PlGF), measurable in the maternal circulation, may have this discriminatory capacity. Plasma PlGF was measured in women presenting with suspected fetal growth restriction (FGR; ultrasound fetal abdominal circumference <10th percentile for gestational age) at sites in Canada, New Zealand and the United Kingdom. When available, placenta tissue underwent histopathological examination for lesions indicating placental dysfunction, blinded to PlGF and clinical outcome. Lesions were evaluated according to pre-specified severity criteria and an overall severity grade was assigned (0-3, absent to severe). Low PlGF (concentration <5th percentile for gestational age) to identify placental FGR (severity grade≥2) was assessed and compared with routine parameters for fetal assessment. For all cases, the relationship between PlGF and the sampling-to-delivery interval was determined. Low PlGF identified placental FGR with an area under the receiver-operator characteristic curve of 0.96 [95% CI 0.93-0.98], 98.2% [95% CI 90.5-99.9] sensitivity and 75.1% [95% CI 67.6-81.7] specificity. Negative and positive predictive values were 99.2% [95% CI 95.4-99.9] and 58.5% [95% CI 47.9-68.6], respectively. Low PlGF outperformed gestational age, abdominal circumference and umbilical artery resistance index in predicting placental FGR. Very low PlGF (<12 pg/mL) was associated with shorter sampling-to-delivery intervals than normal PlGF (13 vs. 29.5 days, P < 0.0001). Low PlGF identifies small fetuses with significant underlying placental pathology and is a promising tool for antenatal discrimination of FGR from fetuses who are constitutionally-small.

8 July 2016 in Obstetric Medicine
Verified
Journal Article
Closed access
KDKate Duhig
Kate Duhig
LCLucy C Chappell
Lucy C Chappell
ASAndrew H Shennan
Andrew H Shennan
Oxidative stress is implicated in the pathophysiology of many reproductive complications including infertility, miscarriage, pre-eclampsia, fetal growth restriction and preterm labour. The presence of excess reactive oxygen species can lead to cellular damage of deoxyribonucleic acids, lipids and proteins. Antioxidants protect cells from peroxidation reactions, limiting cellular damage and helping to maintain cellular membrane integrity. There is overwhelming evidence for oxidative stress causing harm in reproduction. However, there is sparse evidence that supplementation with commonly used antioxidants (mostly vitamins C and E) makes any difference in overcoming oxidative stress or reversing disease processes. There may be potential for antioxidant therapy to ameliorate or prevent disease, but this requires a thorough understanding of the mechanism of action and specificity of currently used antioxidants.

26 December 2014 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Open access
PDF file
HNHl Nathan
Hl Nathan
AAA El Ayadi
A El Ayadi
NHNl Hezelgrave
Nl Hezelgrave
PSP Seed
P Seed
EBE Butrick
E Butrick
ASAh Shennan
Ah Shennan
Objectives: To compare the predictive value of the shock index (SI) with conventional vital signs in postpartum haemorrhage (PPH), and to establish ‘alert’ thresholds for use in low‐resource settings.Design: Retrospective cohort study.Setting: UK tertiary centre.Population: Women with PPH ≥1500 ml (n = 233).Methods: Systolic blood pressure (BP), diastolic BP, mean arterial pressure, pulse pressure, heart rate (HR) and SI (HR/systolic BP) were measured within the first hour following PPH. Values measured at the time of highest SI were selected for analysis. The area under the receiver operating characteristic curve (AUROC) for each parameter, used to predict admission to an intensive care unit and other adverse outcomes, was calculated. Sensitivity, specificity and negative/positive predictive values determined thresholds of the best predictor.Main outcome measures: Intensive care unit (ICU) admission, blood transfusion ≥4 iu, haemoglobin level <7 g/dl, and invasive surgical procedures.Results: Shock index has the highest AUROC to predict ICU admissions (0.75 for SI [95% CI 0.63–0.87] compared with 0.64 [95% CI 0.44–0.83] for systolic BP). SI compared favourably for other outcomes: SI ≥0.9 had 100% sensitivity (95% CI 73.5–100) and 43.4% specificity (95% CI 36.8–50.3), and SI ≥1.7 had 25.0% sensitivity (95% CI 5.5–57.2) and 97.7% specificity (CI 94.8–99.3), for predicting ICU admission.Conclusions: Shock index compared favourably with conventional vital signs in predicting ICU admission and other outcomes in PPH, even after adjusting for confounding; SI <0.9 provides reassurance, whereas SI ≥1.7 indicates a need for urgent attention. In low‐resource settings this simple parameter could improve outcomes. It was not possible to adjust for resuscitative measures administered following vital sign measurement that may have influenced the outcome.

14 September 2021 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Open access
PDF file
ASAndrew Shennan
Andrew Shennan
LSLisa Story
Lisa Story
BJBo Jacobsson
Bo Jacobsson
WGWilliam A. Grobman
William A. Grobman
TBthe FIGO Working Group for Preterm Birth
the FIGO Working Group for Preterm Birth
Cervical cerclage is an intervention which when given to the right women can prevent preterm birth and second‐trimester fetal losses. A history‐indicated cerclage should be offered to women who have had three or more preterm deliveries and/or mid‐trimester losses. An ultrasound‐indicated cerclage should be offered to women with a cervical length <25 mm if they have had one or more spontaneous preterm birth and/or mid‐trimester loss. In high‐risk women who have not had a previous mid‐trimester loss or preterm birth, an ultrasound‐indicated cerclage does not have a clear benefit in women with a short cervix. However, for twins, the advantage seems more likely at shorter cervical lengths (<15 mm). In women who present with exposed membranes prolapsing through the cervical os, a rescue cerclage can be considered on an individual case basis, taking into account the high risk of infective morbidity to mother and baby. An abdominal cerclage can be offered in women who have had a failed cerclage (delivery before 28 weeks after a history or ultrasound‐indicated [but not rescue] cerclage). If preterm birth has not occurred, removal is considered at 36–37 weeks in women anticipating a vaginal delivery.

1 March 2020 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
ASAndrew Shennan
Andrew Shennan
MCManju Chandiramani
Manju Chandiramani
PBPhillip Bennett
Phillip Bennett
ADAnna L David
Anna L David
JGJoanna Girling
Joanna Girling
JCJenny Carter
Jenny Carter

28 February 2018 in F1000Research
Verified
Journal Article
Open access
PDF file
KDKate Duhig
Kate Duhig
BVBrooke Vandermolen
Brooke Vandermolen
ASAndrew Shennan
Andrew Shennan
Pre-eclampsia is a leading cause of maternal mortality, responsible annually for over 60,000 maternal deaths around the globe. Pre-eclampsia is a multisystem disease featuring hypertension, proteinuria, and renal, hepatic, and neurological involvement. Diagnosis is often elusive, as clinical presentation is highly variable. Even those with severe disease can remain asymptomatic. Angiogenic factors are emerging as having a role in the diagnosis of pre-eclampsia and in prognostication of established disease. In this article, we summarize new developments and focus on angiogenic biomarkers for prediction of disease onset. We also discuss recent advances in management strategies for patients with hypertensive disorders of pregnancy.